This finding indicates that lncRNA-NEAT1-miR-324-5p-KCTD20 controlling pathway may be an effective medicinal target for the glioma treatment, and lncRNA-NEAT1 can as a sign of prognosis for glioma patients. Here, KCTD20 is linked to central nervous system cancer.